Evaluation of the PillCam™ Colon Capsule Endoscopy (PCCE) in Detection & Classification of Ulcerative Colitis

This study has been completed.
Sponsor:
Information provided by:
Given Imaging Ltd.
ClinicalTrials.gov Identifier:
NCT00604422
First received: January 24, 2008
Last updated: March 10, 2010
Last verified: March 2010

January 24, 2008
March 10, 2010
April 2007
February 2010   (final data collection date for primary outcome measure)
Agreement level between capsule and colonoscopy in classifying colitis into the above (see section 3.1) categories. [ Time Frame: within 7 days ] [ Designated as safety issue: No ]
Accuracy parameters (sensitivity, specificity, NPV, PPV) of PCCE compared to standard colonoscopy [ Time Frame: within 7 days ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00604422 on ClinicalTrials.gov Archive Site
  • Number, type and severity of adverse events with both PCCE and standard colonoscopy [ Time Frame: Within 7 days ] [ Designated as safety issue: No ]
  • Accuracy parameters for detecting active UC [ Time Frame: within 7 days ] [ Designated as safety issue: No ]
  • Disease severity scoring index for both PCCE and .standard colonoscopy [ Time Frame: within 7 days ] [ Designated as safety issue: No ]
  • Colon cleansing level score for both PCCE and standard colonoscopy. [ Time Frame: within 7 days ] [ Designated as safety issue: No ]
  • Grading of the bubbles interference at the colon for PCCE. [ Time Frame: Within 7 days ] [ Designated as safety issue: No ]
  • Percentage of excreted colon capsules [ Time Frame: Within 7 Days ] [ Designated as safety issue: No ]
  • PCCE transit time from ingestion to excretion and colon transit time [ Time Frame: Within 7 Days ] [ Designated as safety issue: No ]
  • Number, type and severity of adverse events with both PCCE and standard colonoscopy [ Time Frame: Within 7 days ] [ Designated as safety issue: No ]
  • Number of findings detected by PCCE compared to number of findings detected by standard colonoscopy [ Time Frame: within 7 days ] [ Designated as safety issue: No ]
  • Colon cleansing level score for both PCCE and standard colonoscopy. [ Time Frame: within 7 days ] [ Designated as safety issue: No ]
  • Percentage of excreted colon capsules [ Time Frame: within 7 days ] [ Designated as safety issue: No ]
  • PCCE transit time per anatomic location (stomach, small bowel, colon) [ Time Frame: within 7 days ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Evaluation of the PillCam™ Colon Capsule Endoscopy (PCCE) in Detection & Classification of Ulcerative Colitis
Evaluation of the PillCam™ Colon Capsule Endoscopy (PCCE) in Detection & Classification of Ulcerative Colitis

To evaluate the ability of the PillCam® Colon Capsule Endoscope to detect and classify Ulcerative colitis

Ulcerative colitis (UC) is a disorder of unknown origin that may be characterized by acute and chronic inflammation of the colon. The extent of the colonic mucosal inflammation varies among individuals, but the disease almost always involves the rectum. Ulcerative colitis has required evaluation by colonoscopy to determine the extent and severity of the disease. The PillCam platform offers an alternative approach for endoscopic visualization of the colon using capsule endoscopy, a swallowable device which contains imagers, light sources, a power source and a RF transmitter. Advantages of the PillCam platform include the elimination of the need for conscious sedation, the minimally invasive, painless nature of the exam, and the ability to pursue normal daily activities immediately following the procedure . Furthermore, compared to standard colonoscopy, the PillCam platform may be more readily accepted by the subjects, thereby improving subjects' willingness to undergo a diagnostic evaluation of the colon.

The PillCam® SB capsule (formerly M2A® Capsule) that was FDA-approved in August 2001 for small bowel evaluation has been ingested to date by more than 700,000 people worldwide and is well accepted by patients and physicians as well as the professional societies. However, adequate visualization of the colon cannot be achieved with the standard PillCam™ SB capsule because of the anatomical and physiological properties of the colon which are significantly different than the small bowel. Moreover, other issues that limit the evaluation of the colonic mucosa by the standard PillCam™ SB procedure include an unsatisfactory level of colon cleanliness and slow progression of the PillCam™ SB capsule through the colon during the desired examination time. Therefore, the development and introduction of a specially designed, customized colon capsule combined with a dedicated capsule colonoscopy procedure protocol will allow for more efficient evaluation of the colonic mucosa. Further details of the PillCam® Colon Capsule Endoscope (PCCE) can be found in the device description section.

In previous studies, the PillCam colon platform has been shown to be safe and to be able to demonstrate colon polyps and cancers. This study is an extension to a trial evaluating the use of PCCE in ulcerative colitis that has already been completed in Hong Kong (n=40). This study is designed to assess the ability of the capsule to accurately detect inflammatory lesions and thus classifying the extent and severity of disease in subjects with ulcerative colitis in comparison to traditional colonoscopy.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

Subjects that are indicated for standard colonoscopy due to suspected or known Ulcerative colitis disease

The study population will consist of subjects who fulfill all the inclusion criteria and none of the exclusion criteria.

  • Colonic Disease
  • Ulcerative Colitis
Not Provided
A
Subjects that are indicated for standard colonoscopy due to suspected or known Ulcerative colitis disease
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
97
March 2010
February 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects 18-70
  • Suspected or known ulcerative colitis patients

Exclusion Criteria:

  • Subject has dysphagia
  • Subject has congestive heart failure
  • Subject who can not tolerate bowel preparation
  • Poor bowel preparation
  • Subject has renal insufficiency
  • Subject is known or is suspected to suffer from intestinal obstruction.
  • Subject has a cardiac pacemaker or other implanted electro-medical devices.
  • Subject is pregnant
  • Subject is expected to undergo MRI examination within 7 days after ingestion of the capsule.
  • Subject has had prior abdominal surgery of the gastrointestinal tract other than uncomplicated procedures that would be unlikely to lead to bowel obstruction based on the clinical judgment of the investigator.
  • Subject has any condition, which precludes compliance with study and/or device instructions.
  • Subject suffers from life threatening conditions
  • Subject is currently participating in another clinical study
  • Subject has constipation (less than 3 bowel movements/week)
  • Subject has known slow gastric emptying time
Both
18 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
Hong Kong,   Singapore,   Taiwan
 
NCT00604422
MA-107
No
Hilla Debby- Director Clinical Affairs, Given Imaging Ltd.
Given Imaging Ltd.
Not Provided
Principal Investigator: Josef Sung, Prof. Chinese University of Hong Kong
Given Imaging Ltd.
March 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP